Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities

Dysfunctional protein communities drive disease

Proteins have generally been studied as isolated entities, but in nature function in protein communities - interconnected networks of dynamic protein interactions. Medical researchers have been limited by an incomplete understanding of how these communities impact common diseases, lowering the likelihood of successful drug development.

Reshaping protein communities to treat common diseases

Interline Therapeutics uses genomics, proteomics, structural biology and computational chemistry to systematically map and modulate protein communities. Interline is leveraging recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas:

• Genomics: Prioritize genetic variants that drive disease by altering protein communities
• Communities: Identify the specific molecular mechanisms through which these variants change protein community dynamics, enabled by the application of machine learning
• Modulators: Discover and characterize drugs that reshape these communities

The discovery platform will allow the company to identify new medicines targeting genetically validated signaling pathways and ensure that drug candidates comprehensively correct dysfunctional disease networks.

Interline was co-founded by CEO Zachary Sweeney, a scientist with a track record of growing and leading successful drug discovery groups. Company leaders bring decades of experience discovering innovative medicines at Amgen, Denali Therapeutics, Genentech, Novartis and Nurix. The team includes Nick Galli, Chief Operating Officer, Don Kirkpatrick, Chief Technology Officer, Mario Cardozo, Vice President Computational Chemistry and Cheminformatics, Anj Saha, Vice President Discovery Pharmacology and David Tully, Vice President Medicinal Chemistry.

“Biomedical research is newly enabled by advances in human genomic and proteomic technologies,” said Zachary Sweeney, CEO. “We are excited to collaborate with leading research groups to develop a protein-focused roadmap for precision medicine.”

The company will continue to collaborate with Foresite Labs in the fields of data science and genomics. Interline also launches with foundational collaborations with University of California San Francisco and Memorial Sloan Kettering Cancer Center, as well as an internationally recognized team of founding scientific advisors, including:

• John Chodera, PhD, Associate Member and Laboratory Director, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
• Wade Harper, PhD, Chairman and Bert and Natalie Vallee Professor of Molecular Pathology and Cell Biology, Harvard Medical School
• Nevan J. Krogan, PhD, Professor, Cellular and Molecular Pharmacology, UCSF, Director, Quantitative Biosciences Institutes, and Senior Investigator, Gladstone Institutes
• Brenda Schulman, PhD, Director, Molecular Machines and Signaling, Max Planck Institute of Biochemistry
• Mike Varney, PhD, Former Executive Vice President Research and Early Development of Genentech

“Interline has assembled a world-class set of scientific advisors and an outstanding leadership team,” said Mike Varney, member of the company’s Board of Directors. “The company has made great progress toward mapping and understanding the perturbations in protein dynamics caused by genetic mutations, and leveraging these insights to correct the protein communities found in cancer and inflammation.”

“By creating a platform to discover, understand and re-engineer protein interactions, we will find new approaches to treat debilitating diseases,” commented Vikram Bajaj, PhD, co-founder and CEO of Foresite Labs. “Zach and the Interline team possess an incredible breadth of experience, and we are thrilled to help accelerate Interline’s growth.”

Jay Parrish, PhD and Venture Partner at ARCH Venture Partners said, “Our investment in Interline Therapeutics reflects our commitment to their vision of protein-centric systems biology drug discovery. The platform allows for unique insights into mechanisms of serious illnesses with high unmet need, while delivering novel paths and high-impact therapeutics to tackle validated disease targets.”

For more information about Interline Therapeutics, please visit www.interlinetx.com.

Dr. Chodera has served as a scientific advisor for and has financial interests in Interline Therapeutics, and has also provided consulting and advisory services to Foresite Labs. Memorial Sloan Kettering Cancer Center (MSK) has intellectual property rights and associated financial interests related to Interline Therapeutics by virtue of licensing agreements between MSK and Interline Therapeutics.

About Interline Therapeutics

Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease. Interline was incubated by Foresite Labs and is headquartered in South San Francisco, CA. For more information, please visit www.interlinetx.com.

About Foresite Labs

Foresite Labs is a center for entrepreneurial innovation at the nexus of data science and healthcare. Based in San Francisco and Boston, Foresite Labs partners with next generation healthcare entrepreneurs to launch life sciences and healthcare companies that use the tools of data science to solve our greatest unmet medical needs.

About Foresite Capital

Foresite Capital is a multi-stage healthcare and life sciences investment firm with approximately $4 billion in assets under management. The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Foresite Capital uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare. Founded in 2011, Foresite Capital is based in San Francisco. For more information, please visit www.foresitecapital.com.

About ARCH Venture Partners

ARCH Venture Partners invests in advanced technology companies and is one of the largest early stage venture firms in the United States. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market. For more information, visit www.archventure.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005154/en/